论文部分内容阅读
Objective: To evaluate the efficacy and safety of Endostar combined with concurrent chemoradiotherapy (CCRT) in patients with stage Ⅲ non-small cell lung cancer (NSCLC).Methods: Patients with unresectable stage Ⅲ NSCLC were eligible.Patients received Endostar (7.5 mg/m2/d) through 7 d at weeks 1, 3, 5, and 7, and two cycles of docetaxel (65 mg/m2)and cisplatin (65 mg/m2) on days 8 and 36, with concurrent thoracic radiation at 60 to 66 Gy.Primary end points included short-term efficacy and treatment-related toxicity of Endostar combined with CCRT.